A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects
Status:
Completed
Trial end date:
2021-08-19
Target enrollment:
Participant gender:
Summary
The study was designed as a single-site, randomized, open-label, crossover under fasted
conditions. A single oral dose of 0.6 mg Liraglutide injection and Victoza® was given to the
32 healthy Chinese adult male volunteers.Blood samples were collected up to 72 h after
administration.The primary pharmacokinetic endpoints were AUC0-t, AUC0-∞, and Cmax. Safety
profile and immunogenicity data were collected from each subject.